New Two-Drug attack on advanced cancers enters human testing

NCT ID NCT07448116

Recruiting now Disease control Sponsor: Betta Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new combination of two drugs, MCLA-129 and ensartinib, for people with advanced solid tumors that have a specific genetic marker (MET). The main goals are to find a safe and effective dose and to see if the combination can shrink tumors or slow their growth. It is for adults whose cancer has progressed after standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID ADVANCED TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID ADVANCED TUMOR